INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

NCT03837509 PHASE1, PHASE2 TERMINATED Results posted

The purpose of this study is to evaluate the safety and antitumor activity of INCB001158 in combination with daratumumab SC, compared with daratumumab SC alone, in participants with relapsed or refractory multiple myeloma.

Details

Lead sponsor	Incyte Corporation
Phase	PHASE1, PHASE2
Status	TERMINATED
Enrolment	15
Start date	Wed Sep 25 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Relapsed or Refractory Multiple Myeloma

Interventions

• INCB001158
• Daratumumab SC

Countries

United States, Germany, Spain